Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.
Latest story Refreshed every 5 minutes; wire stories every 15 minutesAbout this data